公司核心技术与产品 - Izotropic公司专注于商业化IzoView Breast CT成像系统 该系统旨在通过更精确的筛查、诊断和治疗手段改善乳腺癌检测效果 [2][3] - 该技术可检测小至2毫米的癌症病灶 而当前标准护理的平均检测尺寸为11毫米 意味着可提前12至18个月发现癌症 [4] - 公司近期宣布开发出独有的AI技术能力 该技术预计将随时间推移获得市场认可 [5] 商业化战略与市场定位 - 商业化策略分阶段在欧洲和美国推进 初期重点面向医院、医疗机构和影像诊所销售设备 [6] - 欧美市场合计占全球该类设备市场份额近50% [6] - 公司认为其可能成为大型企业的收购目标 因后者若希望维持市场份额需通过收购介入该领域 [5] 知识产权与竞争优势 - 公司通过专利组合、商业秘密和产品构建知识产权保护体系 [5] - 技术优势体现在对早期侵袭性癌症的检测能力上 当前标准护理在该领域存在显著不足 [4] 监管进展与市场机会 - 产品开发符合FDA标准 若获得FDA批准将打开全球市场机会 [3][6] - 目前正通过临床验证支持商业化进程 并已观察到显著早期需求 [5]

- U.S. patent protection covers computer-aided diagnosis (“CADx”) with breast CT - - Izotropic holds the exclusive rights to this patent and breast CT technology under global license agreement - - CADx upgrade to be integrated into IzoView Breast CT post-initial market launch, feature may be offered as an upgrade incentive to early adopters - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropi ...

  - Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT - - Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge - - AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) ( ...

- Proprietary algorithm positions IzoView to redefine global standards and expectations for image quality and safety in breast CT - - Trained on 15 years of specialized breast CT data and protected as a trade secret, giving Izotropic a durable competitive edge - - AI enhances IzoView’s image quality by reducing CT image noise without increasing radiation dose - VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (F ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company's awareness initiatives. BreastCT.com has been created as a c ...

VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, announces the launch of BreastCT.com, a new online platform supporting the Company's awareness initiatives. BreastCT.com has been created as a c ...

The updated web presence features streamlined navigation and enriched content, including new presentations, video materials, and messaging that communicates Izotropic's value proposition, clinical direction, and strategic focus. Izotropic Introduces New Corporate Website & Brand Identity August 12, 2025 8:00 AM EDT | Source: Izotropic Corporation Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - August 12, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic ...

- IzoView optimized for AI-readiness, addressing a critical need as imaging centers adopt smart workflows and algorithmic support tools VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 05, 2025 (GLOBE NEWSWIRE) -- via IBN - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of breast cancers, provides ...

- Company positioned to lead in dense breast imaging, where rising incidence and new screening mandates are expanding access to advanced technologies - IzoView optimized for AI-readiness, addressing a critical need as imaging centers adopt smart workflows and algorithmic support tools - Global breast imaging market projected to reach $8.69 billion by 2030, with IzoView addressing key clinical and commercial trends driving demand VANCOUVER, British Columbia, and SACRAMENTO, Calif., Aug. 05, 2025 (GLOBE NEWSW ...

The breast imaging market is dominated by traditional mammography, digital breast tomosynthesis ("DBT", "3D mammography"), ultrasound, and MRI technologies, each of which has established clinical applications with well-known limitations. Mammography and DBT remain the primary 2D-based screening tools, yet their sensitivity decreases in approximately 50%+ of women with dense breast tissue1, where overlapping structures under breast compression can obscure lesions and tumours. Ultrasound is often used as a su ...